•Bevacizumab—In the same year that the N9741 trial was reported, results from another landmark study were published, which evaluated bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF). This trial compared IFL/bevacizumab, weekly bolus 5-FU/LV/bevacizumab, and IFL/placebo, with treatment continuing until disease progression.[19,20] Compared to IFL/placebo, IFL/bevacizumab resulted in a higher response rate (45% vs 35%, P < .05), prolongation of median progression-free survival by 4.4 months (10.6 vs 6.2 months, P < .001) and median overall survival by 4.7 months (20.3 vs 15.6 months, P < .001). It is important to note that patients who were treated with first-line IFL/placebo could not cross over to second-line bevacizumab; thus, the difference in progression-free survival was translated 1:1 into overall survival.
Once the safety of IFL/bevacizumab had been established in the phase III trial, the FU/LV/bevacizumab arm of the trial was discontinued with 110 patients enrolled. The results in this relatively small patient sample were later published, showing similar overall and progression-free survival for 5-FU/LV/bevacizumab and IFL/placebo with a trend in favor of the bevacizumab-containing arm. The results of adding bevacizumab to 5-FU/LV alone (without irinotecan or oxaliplatin) are important for patients who cannot tolerate or do not wish to be treated with the newer cytotoxic agents. A combined analysis of three randomized trials (N = 500) of bevacizumab added to 5-FU/LV alone showed significantly greater overall survival and progression-free survival (more than 3.3 and 3.2 months), compared with the combined control group of chemotherapy without bevacizumab (5-FU/LV alone, 5-FU/LV/placebo, or IFL/placebo). As the front-line use of IFL is (fortunately) diminishing, the efficacy and safety of bevacizumab had to be assessed in combination with oxaliplatin-containing regimens and with FOLFIRI.
For the TREE studies, two sequential randomized trials compared three oxaliplatin-based regimens with bevacizumab (TREE-2) or without bevacizumab (TREE-1). In each trial, oxaliplatin was paired with either infusional 5-FU/LV (mFOLFOX6, Table 2), bolus 5-FU/LV (bFOL), or capecitabine (XELOX). Results of TREE-1 and TREE-2 were recently presented together at the American Society of Clinical Oncology (ASCO) annual meeting (Table 3). Comparisons across trials indicate that bevacizumab enhances the efficacy of each treatment in terms of response rate, time to progression, and overall survival (Table 2). At a median follow-up of 27 months, overall survival for all bevacizumab-containing regimens combined (TREE-2) was 24.4 months, compared with 18.2 months without bevacizumab (TREE-1). The addition of bevacizumab did not increase the median time to treatment failure, a composite endpoint of efficacy and toxicity. The lack of effect of bevacizumab on this endpoint is conceivably due to the cumulative toxicity associated with oxaliplatin, which typically does not allow patients to remain on therapy for more than 6 months.
Most recently, a large randomized, placebo-controlled phase III trial (NO16966) investigated the addition of bevacizumab to XELOX or FOLFOX. This trial clearly demonstrated that bevacizumab increases progression-free survival when added to an oxaliplatin-based regimen in the first-line therapy of mCRC. The results of this trial and its implications for current clinical practice are discussed further below.
In a design similar to that of the TREE trials, the Bolus, Infusion, or Capecitabine with Camptosar ± Celecoxib (BICC-C) studies investigated the optimal fluoropyrimidine backbone for the addition of irinotecan in first-line treatment of mCRC. When bevacizumab was approved, the trial was amended to eventually compare modified IFL/bevacizumab (n = 60) with FOLFIRI/bevacizumab (n = 57) at a phase II level. These data were most recently presented at the 2007 ASCO Gastrointestinal Cancers Symposium; the median overall survival (not yet reached vs 19.2 months, P = .007) and progression-free survival (11.2 vs 8.3 months, P = .28) were greater with FOLFIRI plus bevacizumab than with bevacizumab plus mIFL. Of note, 1-year survival was markedly higher with FOLFIRI plus bevacizumab than with bevacizumab plus mIFL (87% vs 61%). Response rates were similar (54% and 53%) with the two regimens.
Bevacizumab has also been investigated in the second-line setting combined with oxaliplatin-based regimens. In the Eastern Cooperative Oncology Group (ECOG) E3200 phase III trial of FOLFOX4 plus bevacizumab (10 mg/kg) involving patients in whom irinotecan-based therapy had failed, FOLFOX4/bevacizumab significantly increased median progression-free survival (7.2 vs 4.8 months, P < .0001) and median overall survival (12.9 vs 10.8 months, P < .002) compared to FOLFOX4 alone. This trial included a bevacizumab-only arm, in which progression-free survival was inferior to FOLFOX4 alone (2.7 vs 4.8 months, P < .0001). Based on these data, bevacizumab in combination with intravenous 5-FU-based therapies received US Food and Drug Administration (FDA) approval for use in the second-line setting. These results highlight the benefit of combining bevacizumab with a cytotoxic agent such as conventional chemotherapy or, alternatively, with cetuximab, as discussed below. In contrast, the single-agent activity of bevacizumab in mCRC appears to be marginal at best.
•EGFR Antibodies—The other biologic strategy with proof-of-efficacy in mCRC is to target the extracellular domain of the epidermal growth factor receptor (EGFR) with monoclonal antibodies. The first antibody developed and eventually FDA-approved was cetuximab. The only currently published randomized trial of this agent for mCRC was conducted in the salvage setting of irinotecan-refractory disease. The addition of cetuximab to irinotecan compared to cetuximab alone in irinotecan-refractory patients significantly improved response (22.9% vs 10.8%) and time to progression (4.1 vs 1.5 months). Bevacizumab appears to increase the therapeutic benefit in an irinotecan-refractory population as well. When the combination of bevacizumab/cetuximab/irinotecan was evaluated in the BOND-2 trial and compared to historical controls receiving cetuximab/irinotecan alone in this setting, time to progression and response rate were greater in those receiving bevacizumab.[24,25]
More recently, very promising results have been presented for the monoclonal anti-EGFR antibody panitumumab. Unlike cetuximab, which is a chimeric IgG1 antibody, panitumumab is a fully human monoclonal IgG2 antibody. The pivotal trial was conducted in the third-line setting. Patients with mCRC who had failed oxaliplatin and irinotecan received either panitumumab plus best supportive care or best supportive care alone. Those receiving panitumumab experienced a 46% reduction in tumor progression compared to best supportive care alone (P < .000000001). As of early 2007, only limited data exist on the combination of panitumumab with modern cytotoxic combination regimens such as FOLFIRI. Therefore, panitumumab was approved as a single-agent salvage therapy option in patients with mCRC refractory to 5-FU, irinotecan, and oxaliplatin.
Based on the available clinical data, FOLFIRI, FOLFOX, and XELOX are appropriate chemotherapy backbones in the first-line therapy of mCRC, to which bevacizumab should be added to maximize efficacy. 5-FU/LV plus bevacizumab is an alternative for patients not considered candidates for irinotecan- or oxaliplatin-based combination therapy.
Dr. Grothey has received honoraria for consulting from Amgen, Bristol-Myers Squibb, Pfizer, Genentech, and Roche. Dr. Marshall has received research support and honoraria from Pfizer, Sanofi, Genentech, Roche, Bristol-Myers Squibb, Amgen, and Boehringer Ingelheim.
1. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (erratum in Lancet 355:1372, 2000).
2. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005.
3. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000.
4. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) (abstract 512). Proc Am Soc Clin Oncol 20:129a, 2002.
5. Kohne CH, Wils J, Lorenz M, et al: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21:3721-2728, 2003.
6. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000.
7. Kohne C, de Greve J, Bokemeyer C, et al: Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015 (abstract 3525). J Clin Oncol 23(16S):252s, 2005.
8. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000.
9. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
10. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004.
11. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005.
12. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004.
13. Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23:9441-9442, 2005.
14. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001.
15. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566-575, 2002.
16. Kubicka S, Arkenau H, Grothey A, et al: Randomized trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): final results of the safety and efficacy analysis (abstract 277). Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco; January 26-28, 2006.
17. Cassidy J, Clarke S, Diaz Rubio E, et al: First efficacy and safety results from XELOX-1/NO16966, a randomised 2 x 2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC) (abstract LBA3). Ann Oncol 17(suppl 9), 2006.
18. Jordan K, Kellner O, Kegel T, et al: Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 4:56-50, 2004.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
20. Hurwitz H, Fehrenbacher L, Hainsworth J, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005.
21. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Final analysis of the TREE study (abstract 3510). J Clin Oncol 24(18S):148s, 2006.
22. Fuchs CS, Marshall J, Mitchell EP, et al: Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations ± celecoxib in mCRC: Clinical data cut-off September 1, 2006 (abstract 276). Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, Fla; January 19-21, 2007.
23. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract 2). J Clin Oncol 23(16S):1s, 2005.
24. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004.
25. Saltz LB, Lenz H-J, Hochster H, et al: Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (abstract 3508). J Clin Oncol 23(16S):248s, 2005.
26. Peeters M, Van Cutsem E, Siena S, et al: A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC) (abstract CP-1). Presented at the 97th Annual Meeting of the American Association for Cancer Research; Washington, DC; April 1-4 2006.
27. Green EM, Sargent DJ, Goldberg RM, et al: Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741 (abstract 264O). Ann Oncol 15(suppl 3):70, 2004.
28. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24:394-400, 2006.
29. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study (abstract 3504). J Clin Oncol 24(18S):147s, 2006.
30. National Institutes of Health: CONCEPT: Comparison of oxaliplatin versus conventional methods with calcium/magnesium in first-line metastatic colorectal cancer. Available at: www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00129870. Updated November 14, 2006. Accessed March 8, 2007.
31. National Institutes of Health: Combination chemotherapy and bevacizumab with or without erlotinib in treating patients with metastatic colorectal cancer that cannot be removed by surgery. Available at www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00265824. Updated February 20, 2007. Accessed March 8, 2007.
32. National Institutes of Health: A study to compare two Avastin-based treatment regimens for the treatment of metastatic colorectal cancer. Available at www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00114946. Updated May 26, 2006. Accessed March 8, 2007.
33. National Institutes of Health: Cetuximab and/or bevacizumab and combination chemotherapy in treating patients with locally advanced or metastatic colorectal cancer. Available at: www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00265850. Updated March 5, 2007. Accessed March 8, 2007.
34. National Institutes of Health: PACCE: Panitumumab Advanced Colorectal Cancer Evaluation study. Available at www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00115765. Updated February 15, 2007. Accessed March 8, 2007.
35. D'Andre S, Sargent DJ, Cha SS, et al: 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study. Clin Colorectal Cancer 4:325-331, 2005.
36. Mor V, Masterson-Allen S, Goldberg RJ, et al: Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc 33:585-589, 1985.
37. Greenfield S, Blanco DM, Elashoff RM, et al: Patterns of care related to age of breast cancer patients. JAMA 257:2766-2770, 1987.
38. Goldberg RM, Sargent D, Bleiberg H, et al: A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer (abstract 228). Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco; January 26-28, 2006.
39. de Gramont A, Cervantes A, Andre T, et al: OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer (abstract 3525). Proc Am Soc Clin Oncol 23:251, 2004
40. Figer A, Perez N, Carola E, et al: 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer (abstract 3571). Proc Am Soc Clin Oncol 23:263, 2004.
41. Fyfe GA, Hurwitz H, Fehrenbacher L, et al: Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups (abstract 3617). Proc Am Soc Clin Oncol 23:274, 2004.
42. Skillings JR, Johnson DH, Miller K, et al: Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (abstract 3019). J Clin Oncol 23(16S):196s, 2005.
43. Kohne CH, Folprecht G: Current perspectives in the treatment of metastatic colorectal cancer. Ann Oncol 15(suppl 4):iv43-53, 2004.
44. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005.
45. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005.
46. Mass RD, Sarkar S, Holden SN, et al: Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 23(16 suppl):249s, 2005.
47. Grothey A, Sargent D: Randomized study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC), an interim safety analysis: A Dutch Colorectal Cancer Group (DCCG) phase III study (abstract 282). Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta; June 2-6, 2006.
48. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology. Colon Cancer v.1.2005.
49. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005.